TOFA, A Weight Loss Drug That Burns Fat Instead of Killing Appetite

Every diet, and every blockbuster obesity drug of the last five years, works one side of a simple ledger: eat less. The GLP-1 medications (glucagon-like peptide-1 drugs) like Ozempic and Mounjaro turn down hunger, and the pounds follow. A compound that UC Berkeley researchers have now put through its paces in mice works the other side of that ledger entirely, spending more energy rather than taking in less, and in obese animals it stripped away fat while leaving muscle alone. The molecule is an old one, first made in the 1970s and shelved, and its second act is the interesting part.

The compound is called TOFA, short for 5-tetradecyloxy-2-furoic acid, and it belongs to a class of drugs called ACC inhibitors (they block acetyl-CoA carboxylase, an enzyme) that stop the body from building fats like cholesterol and triglycerides. Several reached mid-stage human trials over the years. None got approved, and the reason was a nasty catch.

Blocking fat production, it turned out, tends to push blood triglycerides up rather than down, which is exactly the wrong direction for the heart. TOFA had always been the odd one out here: an ACC inhibitor that lowered blood lipids instead of raising them, and nobody had a good account of why. The Berkeley team, publishing in Science Advances, went looking for the missing mechanism and found that TOFA has a second job. Alongside blocking fat synthesis, it flips on two cellular switches called PPAR alpha and PPAR delta (a family of receptors, the peroxisome proliferator-activated receptors, that regulate how cells handle fat), receptors that tell cells to take up fat and burn it for fuel.

That second job is what makes TOFA behave less like a diet and more like a slightly hotter engine. In the mice, cells worked their way through more fuel with no change in how much the animals ate or moved.

The numbers back the picture. Across the main experiment, groups of 10 mice apiece, obese animals given TOFA burned about 18% more energy than untreated ones, with no rise in body temperature and no extra activity in the cage, and they lost roughly that same fraction of their body weight over the course of treatment. Crucially, the weight came off as fat. Lean muscle mass, measured directly, did not drop, which is the thing that has worried doctors about the appetite-suppressing drugs.

“Body weight responds to two levers: taking in fewer calories, or spending more energy,” says Anders Naar, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study. “GLP-1s work almost entirely on the first, so we went after the second.”

Two Jobs in One Molecule

Why does having two jobs matter so much? Because doing them separately didn’t work. When the team gave mice two different drugs, one to block fat production and one to rev up energy burning, the combination fell short of what TOFA managed on its own. Something about the two actions living inside a single molecule, hitting the same cell at the same time, produced a result the two-drug cocktail could not. The dual mechanism also seems to explain the old mystery: because TOFA is simultaneously telling cells to burn fat, it never triggers the triglyceride spike that sank its cousins. First author Justin Y. Lee, who did the work as a PhD student at Berkeley and is now a postdoctoral researcher at UCSF, describes it as a coordinated response rather than a single blocked pathway, one that helps the body clear excess lipid and glucose more effectively. In the treated mice, insulin sensitivity and blood sugar control both improved, and the fatty-liver features that ride along with obesity eased off too.

A Partner for Ozempic, Not a Rival

There is an obvious question hanging over all this, given how many people are on a GLP-1 already. Would TOFA compete with those drugs, or work alongside them?

Alongside, on the evidence so far. When the researchers paired TOFA with semaglutide or tirzepatide, the GLP-1 drugs sold as Ozempic and Mounjaro, the combinations beat either drug alone on weight, blood sugar, insulin and triglycerides. Naar frames TOFA as complementary rather than a replacement, an energy-out partner to the appetite-suppressing incretins.

The caveats are the size of the building. Everything here happened in mice, and only male mice at that; the researchers left female animals for follow-up work, citing the way estrogen changes the metabolic picture. TOFA has never been given to a person for this purpose, its safety at these doses is not fully worked out, and the lowest effective dose is still unknown. An old tolerability record in rats looks reassuring, but reassuring in rats is not the same as safe in people.

Still, the appeal of an approach that spends energy rather than starving appetite is easy to see. Muscle loss and gastrointestinal misery are the two complaints that dog the current drugs, and a partner that spares muscle, comes as a pill, and might let the injectables be dosed lower would address both. The team has spun out a company, ReRx Therapeutics, to try to carry TOFA toward patients, which is also why the interests here are worth watching closely.

What no mouse can tell us is whether any of this survives the jump to human biology, where a great many promising metabolic compounds have quietly died. That jump is the whole game now.

FAQ